Thermo Fisher Scientific unveils end-to-end diagnostic and lab solutions at ADLM 2026
Thermo Fisher’s presence at ADLM 2026 reflects its ongoing commitment to addressing unmet clinical needs with reliable, purpose-built diagnostic and workflow solutions
28 Jul 2026
Thermo Fisher Scientific will showcase its latest diagnostic innovations, recent regulatory milestones and expanded capabilities at booth 3501 at ADLM 2026, in Anaheim, California.
Innovation to address unmet clinical needs
Thermo Fisher’s specialty diagnostics portfolio addresses high-impact clinical needs across multiple myeloma monitoring with the EXENT® Solution andthe EliA™ CTD 13 Screen.
The EXENT® Solution, a fully integrated and automated mass spectrometry platform designed to aid in the diagnosis of multiple myeloma and related disorders, recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA). By combining increased sensitivity with automated workflows, the EXENT System helps clinical laboratories deliver accurate results, supporting fast, confident diagnoses and more informed clinical decision-making.
The EliA™ CTD 13 Screen received U.S. Food and Drug Administration (FDA) 510(k) clearance in June 2026, providing clinical laboratories with a new option for systemic connective tissue disease (CTD) testing. The assay helps streamline testing workflows with results that support targeted follow-up testing and informed clinical decision-making.
Available on the Phadia™ 250 instrument, EliA CTD 13 Screen is intended to aid in the diagnosis of systemic autoimmune connective tissue diseases, including systemic lupus erythematosus, Sjögren’s syndrome, systemic sclerosis, polymyositis, dermatomyositis and mixed connective tissue disease, when used in conjunction with other laboratory and clinical findings.
Thermo Fisher will also feature its B·R·A·H·M·S™ biomarker testing portfolio, which improves early diagnosis and informs treatment plans for life-threatening illnesses, such as sepsis and preeclampsia.
Anchored by the Thermo Scientific B·R·A·H·M·S KRYPTOR Analyzers, the portfolio includes procalcitonin (PCT) testing for antibiotic stewardship in sepsis management, and the PreClara Ratio™*, which is the first FDA-cleared biomarker test for preeclampsia risk assessment.
Advancing diagnostics through deeper research insights and digital tools
The Thermo Scientific™ TSQ Certis™ Triple Quadrupole Mass Spectrometer** brings high sensitivity and robustness to clinical research workflows including immunosuppressant drug monitoring, toxicology and bioanalysis. Designed for regulated environments, the TSQ Certis supports the analytical rigor that translates research-stage biomarkers into clinical insights.
Also on display, will be the Applied Biosystems™ QuantStudio™ Dx Real-Time PCR System, that supports molecular diagnostics workflows in clinical and public health laboratories, offering a scalable platform for infectious disease testing and pathogen detection.
A recent addition to Thermo Fisher’s diagnostics portfolio is Thermo Scientific™ B·R·A·H·M·S Fast Screen™ PLUS, which completes the company's prenatal screening solution by integrating biomarkers, instrumentation and clinically validated risk assessment algorithms into a connected digital platform designed to support standardized interpretation, consistent reporting and streamlined prenatal screening workflows.
Quality management is a clinical imperative
At ADLM, Thermo Fisher will showcase two complementary solutions that advance quality management beyond routine compliance. The LabLink360™ features Sigma-metric analysis, a global benchmarking tool that enables labs to assess performance and optimize quality control (QC) parameters so that they can identify opportunities to reduce QC burden without compromising performance.
Paired with Thermo Scientific MAS™ Max quality controls, streamlined and automated workflows enable lab technicians to focus more on delivering fast and accurate patient results.
*Brand trademarked in the U.S. only.
**Instruments are for general lab use only. Not for diagnostic purposes.
Follow SelectScience throughout ADLM 2026 for exclusive interviews, daily round-up articles, Scientists' Choice Awards® coverage, and the latest news from the exhibition floor.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
What diagnostic innovations will Thermo Fisher Scientific highlight at ADLM 2026 in Anaheim?
Thermo Fisher Scientific will showcase its latest diagnostic innovations at ADLM 2026 in Anaheim, California, at booth 3501. Key highlights include the EXENT® Solution for multiple myeloma monitoring, the EliA™ CTD 13 Screen for systemic connective tissue disease testing, the B·R·A·H·M·S™ biomarker testing portfolio, and digital quality management tools such as LabLink360™ and Thermo Scientific MAS™ Max quality controls.
How does the EXENT Solution and EliA CTD 13 Screen support clinical laboratories and patient diagnosis?
The EXENT® Solution, a fully integrated automated mass spectrometry platform with FDA 510(k) clearance, aids diagnosis of multiple myeloma and related disorders through increased sensitivity and automated workflows. The EliA™ CTD 13 Screen, also FDA 510(k) cleared, supports systemic autoimmune connective tissue disease diagnosis on the Phadia™ 250 instrument, streamlining workflows and enabling targeted follow-up testing and informed clinical decision-making.
What role do B·R·A·H·M·S biomarkers and digital tools play in Thermo Fisher’s diagnostics portfolio?
Thermo Fisher’s B·R·A·H·M·S™ portfolio, anchored by B·R·A·H·M·S KRYPTOR Analyzers, supports early diagnosis and treatment planning for sepsis and preeclampsia, including procalcitonin (PCT) testing and the PreClara Ratio™ for preeclampsia risk assessment.
Digital and research tools such as the TSQ Certis™ Triple Quadrupole Mass Spectrometer, QuantStudio™ Dx Real-Time PCR System, and B·R·A·H·M·S Fast Screen™ PLUS enhance clinical research, molecular diagnostics, and prenatal screening workflows.